Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Completed 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Thoracic 1Sarcoma 1Gynecologic 1Genitourinary 1Gastrointestinal 1Breast 1

Conditions

Triple Negative Breast Neoplasms 1Sarcoma 1Recurrence 1Prostatic Neoplasms 1Ovarian Neoplasms 1Neoplasms 1Esophageal Neoplasms 1Colorectal Neoplasms 1Carcinoma, Non-Small-Cell Lung 1

Interventions

pembrolizumab 17Surveys and Questionnaires 12Specimen Handling 11Docetaxel 11Nivolumab 9Interviews as Topic 9Standard of Care 8Gemcitabine 8Early Intervention, Educational 8olaparib 7enzalutamide 7Magnetic Resonance Spectroscopy 7Psychiatric Rehabilitation 6Paclitaxel 6durvalumab 5Trastuzumab 5Radiotherapy 5Ipilimumab 5Carboplatin 5Bevacizumab 5pertuzumab 4palbociclib 4cabozantinib 4atezolizumab 4abiraterone 4Therapeutics 4Taxes 4Oxaliplatin 4Methods 4Immunoglobulin G 4

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Prostatic Neoplasms × CLR1404 × Gastrointestinal × Clear all
NCT01495663 2015-02-26

Dose Escalation Study of I-131-CLR1404 in Subjects With Cancer That Does Not Respond to Treatment or Has Returned

Cellectar Biosciences, Inc.

Phase 1 Completed
12 enrolled
BreastGastrointestinalGenitourinaryGynecologicSarcomaThoracic

Carcinoma, Non-Small-Cell Lung, Esophageal Neoplasms, Neoplasms, Ovarian Neoplasms, Prostatic Neoplasms, Recurrence, Sarcoma, Colorectal Neoplasms, Triple Negative Breast Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡